Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma.

Exp Hematol Oncol · 2025 · PMC12482220 · PMID 41029877

Europe PMC DOI

hedged sentence

0.2557

closest p · 5.1× alpha

0.2557

boldest claim

The sentences

did not reach statistical significanceP = 0.2557not close (p > 0.1)

The AUC 0 − 28 values were observed to be elevated in patients with CRS in comparison to those without CRS; however, this difference did not reach statistical significance (median values of 2008586.8 vs. 1559700.1 copies/μg gDNA; P = 0.2557) (see Supplementary Fig. 1).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.